Skip to main content
Profile picture for Jiha Lee, MD

Jiha Lee, MD

Dr. Lee is a rheumatologist in Michigan. Her research focuses on bridging to fields of rheumatology and geriatrics to improve the care of older adults with rheumatic diseases.

Articles By Jiha Lee, MD

Dental tools

Three Tips to Stay on Muscarinic Agonists in Sjögren's Disease

Resolution of dryness remains a key unmet need for patients with Sjögren disease (SjD), as highlighted by the Sjögren SIG session “How to treat SjD” on the final day of APLAR 2026. A rheumatology talk in the session noted that recent phase III trials of ianalumab, dazodalibep and telitacicept improved ESSDAI scores, with only some evidence of benefit for dryness itself. Symptomatic care therefore still carries the load. Masafumi Moriyama, DDS, PhD, offered practical insight from the oral health side.

Read Article
knee,pain3,target

Intra-Articular Injections for Knee OA: Options, Evidence, and no Clear Winner

At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im (Dongguk University, Korea). The products fall into three tiers: symptom-modifying, biologic/regenerative and structure-oriented. The pipeline is encouraging, but the evidence is uneven and often thin.

Read Article
ILD.colors

RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest

At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.

Read Article
psA.fil_.Hands_.jpg

What’s New in Psoriatic Arthritis: A Whirlwind Tour

At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.

Read Article
elderly hands

A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology

A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.

Read Article
Sjogren.eye.mouth

Ianalumab Shows Phase 3 Success in Sjögren’s: Is It Clinically Meaningful?

On the final day of ACR25, late-breaking abstract #24 drew particular attention, presenting results from the first positive Phase 3 trials of a potential systemic treatment for a disease that has long lacked one.

Read Article
older woman with clasped hands

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention

At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.

Read Article
elderly hands

Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults

As the population ages globally, rheumatologists are caring for an increasingly older patient population more than ever before. In RA alone, nearly 40 percent of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental question: do we really know how best to treat older adults with rheumatic diseases?

Read Article
human figures on blue circle

ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA

At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.

Read Article
PsA.Hands_.jpg

From Domains to Decisions: Personalizing PsA Care with Data

At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.

Read Article
×